Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 762 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Cemiplimab-rwlc in Combination with Platinum-Based Chemotherapy for Advanced NSCLC November 25, 2022 Cómo los ensayos clínicos pueden llevar a un tratamiento que salve... October 12, 2023 Biomedical Engineering Student Invents Device for At-Home Breast Cancer Screening January 6, 2021 Biomarker Data from the KAITLIN Study in High-Risk Early Breast Cancer May 7, 2021 Load more HOT NEWS Study Says Exercise Combats Side Effects of Chemo and Other Meds... Encouraging Antitumour Activity of First-Line Atezolizumab Plus Paclitaxel and Bevacizumab in... A New FDA Approval Furthers the Role of Genomics in Cancer... Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο
